The Union government has allowed commercial export of Covishield and Covaxin considering the sufficient stock of the COVID-19 vaccines available with states and Union Territories as well as with manufacturers, official sources said on Thursday.
However, the quantity of Covid vaccines to be exported will be decided by the government every month to ensure there is no dearth of domestic availability.
India recently resumed Covid vaccine supply to the UN-backed COVAX with the government allowing Serum Institute of India (SII) to export 50 Lakh doses of Covishield to Nepal, Tajikistan, Bangladesh and Mozambique.
The Covishield shipment will reach Nepal and Tajikistan this week.
"More than 22.72 crore balance and unutilized COVID-19 vaccine doses are still available with the states and Union Territories. The vaccine production is increasing and there will be surplus supplies.
"Keeping this in mind, a decision has been taken to allow commercial export of Covishield and Covaxin," an official source told PTI.
Prakash Kumar Singh, Director, Government and Regulatory Affairs at SII had recently communicated to the Union Health Ministry that the Pune-based firm has 24,89,15,000 doses of Covishield and the stock is increasing every day.
The official, however stressed, "The quantity of vaccines to be exported will be decided by the government on a monthly basis to ensure that domestic availability is not hampered in any way."
About 31 crore doses of Covishield and Covaxin are expected to be received by the government from SII and Bharat Biotech in December, while Zydus Cadila is likely to supply around two crore jabs of its three-dose Covid vaccine ZyCoV-D by that time.
The government recently permitted the export of 2 crore doses of COVID-19 vaccine Covovax, produced in India by SII, to Indonesia. The jab is yet to be approved for emergency use in the country, according to official sources.
The first shipment of Covovax will reach Indonesia this week.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)